← Friday, 2 October 2026
75
Impact · ElevatedSEC 8-K · 2 Oct 2026, 20:37 UTC · primary source

Silo Pharma files 8-K with material agreement and unregistered sales

Why it matters

An 8-K 1.01 filing signals a material agreement that could affect revenue, partnerships, or financial position; Item 3.02 suggests unregistered securities sales, indicating potential dilution or funding needs. Without full details, direction is unclear but the dual-item disclosure warrants attention as these are not routine filings.

In plain language

Silo Pharma announced it signed a significant deal and sold securities (likely shares or warrants) to raise money. Both moves matter to investors since they could affect the company's value and direction.

Exposure
Price check
not measured: no fresh price at the time of scoringHow this is measured

Information only. AURA does not give buy or sell recommendations.